Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human
Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I
inhibitor payload, which combine the ability of antibodies to specifically target tumour
cells with the highly potent killing activity of drugs with payloads too toxic for systemic
administration. This is a phase I study to evaluate the safety, tolerability and
effectiveness of TQB102 injection in subjects with advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.